Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin
Completed
- Conditions
- Curatively Resected Stage III Colon Cancer
- Registration Number
- NCT00977717
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.
- Detailed Description
To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA isolation kit, and SNP polymorphisms will be evaluated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- aged 18 or older
- curatively resected colon adenocarcinoma
- pathologically staged III
- adequate performance status
- adequate major organ functions
- to be treated with adjuvant FOLFOX chemotherapy
- written informed consent
Exclusion Criteria
- those who disagree the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method neuropathy six months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center🇰🇷Seoul, Korea, Republic of